Showing 1221-1230 of 1601 results for "".
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were
- Pulse Biosciences, Inc's CellFX System Performs Well in Sebaceous Hyperplasia Studyhttps://practicaldermatology.com/news/pulse-biosciences-incs-cellfx-system-performs-well-in-sebaceous-hyperplasia-study/2459987/Pulse Biosciences, Inc’s CellFX Nano-Pulse Stimulation system cleared more than 90 percent of sebaceous hyperplasia (SH) lesions in a study presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Study: Isotretinoin Does Not Raise Depression Riskhttps://practicaldermatology.com/news/study-isotretinoin-does-not-raise-depression-risk/2459878/Isotretinoin is not an independent risk factor for depression in adult acne patients, finds new research presented at the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington. “There has been mixed evidence and much debate around the impact of isotretinoin on mo
- Meet AAD's New Officers and Board of Directorshttps://practicaldermatology.com/news/meet-aads-new-officers-and-board-of-directors/2459880/The American Academy of Dermatology (AAD) is set to install four new officers and four new members of its board of directors at the conclusion of the 2019 AAD Annual Meeting in Washington. The new members will also hold the same positions for the American Academy of Dermatology Associat
- Dr. George J. Hruza Named New AAD Presidenthttps://practicaldermatology.com/news/dr-george-j-hruza-named-new-aad-president/2459881/St. Louis dermatologist George J. Hruza, MD, MBA, FAAD, is set to begin his one-year term as president of the American Academy of Dermatology (AAD) at the conclusion of the 2019 AAD Annual Meeting in Washington. “The health care landscape is evolving, and it’s important for de
- Hyperhidrosis May Up Risk for Anxiety, Depression and ADDhttps://practicaldermatology.com/news/hyperhidrosis-may-up-risk-for-anxiety-depression-and-add/2459877/Individuals with hyperhidrosis are more to have anxiety, depression and attention deficit disorder, according to new research presented at the American Academy of Dermatology’s (AAD) 2019 Annual Meeting in Washington. Of the 500 hyperhidrosis patients involved in the study, 13.8 p
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- 2019 Residents of Distinction Return from Caribbean Dermatology Symposiumhttps://practicaldermatology.com/news/2019-residents-of-distinction-return-from-caribbean-dermatology-symposium/2459919/Five dermatology residents have just returned from the 18th Annual Caribbean Dermatology Symposium, held in Grand Cayman Island. Their participation was sponsored by Beiersdorf Inc., as part of the dermMentors™ Resident of Distinction Award™ program. The reside
- Encore Dermatology Shares Positive Pivotal Study Results for Impoyz for the Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/encore-dermatology-shares-positive-pivotal-study-results-for-impoyz-for-the-treatment-of-plaque-psoriasis/2459920/Impoyz Cream (clobetasol propionate) Cream, 0.025% demonstrated efficacy early with 14.2 percent of Impoyz patients achieving treatment success at day 8 versus 1.6 percent in the vehicle group, according to results of a pivitol study that were shared at the 15 th annual Maui Derm Conference. Trea